Publications by authors named "Chunmeng Qin"
Article Synopsis
- * Researchers analyzed data from the FDA Adverse Event Reporting System (FAERS) spanning from 2004 to 2022 to identify agents reported to trigger TLS and assess their associated risks through disproportionality analysis.
- * Results revealed that 164 antineoplastic agents were linked to TLS, with rituximab being the most frequently reported, while tagraxofusp showed the highest adverse reaction signal strength, indicating varying risks across different medications.
Context: In China, HUANGQI is widely used for the treatment of Alzheimer's disease (AD). However, a comprehensive understanding of its mechanism of anti-AD effects is lacking.
Objective: To explore the active ingredients of HUANGQI and its potential targets and mechanisms of action in AD.
Background: At present, drug development for treating Alzheimer's disease (AD) is still highly challenging. Eriodictyol (ERD) has shown great potential in treating AD, but its molecular mechanism is unknown.
Objective: We aimed to explore the potential targets and mechanisms of ERD in the treatment of AD through network pharmacology, molecular docking, and molecular dynamics simulations.
Article Synopsis
- Doxorubicin (DOX) is an effective cancer drug, but its use is limited due to cardiotoxicity (DIC), while eriodictyol (ERD) shows promise in providing heart protection against this side effect.
- This study investigates how ERD protects the heart by analyzing ERD and DIC-targets through various biological databases and conducting network pharmacology and molecular docking analyses.
- Results indicate that ERD interacts with 43 targets related to DIC, with strong binding to key targets and involvement in the ROS pathway, suggesting a multi-targeted cardioprotective effect.
Article Synopsis
- Liujunzi Decoction (LJZD) is being investigated as a treatment for breast cancer, but its active ingredients and how they work are not yet fully understood.
- The study utilized network pharmacology and molecular docking to identify the target genes and mechanisms of LJZD in combating breast cancer.
- Key findings included 126 active ingredients, 241 breast cancer-related targets, and 180 intersecting targets, with core targets identified as FOS and ESR1, and involved signaling pathways like PI3K/Akt and MAPK.
Article Synopsis
- Drug-induced QT prolongation and Torsade de Pointes (TdP) are serious adverse reactions caused by several medications, but there's a lack of comprehensive data on the specific drugs responsible.
- A review of the FDA Adverse Event Reporting System from 2004 to 2022 identified 42,713 reports linked to QT prolongation and TdP, highlighting furosemide as the most frequently reported drug, primarily among antineoplastics.
- The analysis revealed 612 drugs with positive adverse drug reaction signals, indicating significant variability in risk levels among different drug classes, such as psycholeptics and beta-blockers.
Article Synopsis
- Timely recognition and stoppage of drugs causing acute pancreatitis (AP) is crucial for treatment, but information on these drugs is limited.
- An analysis of FDA adverse event reports from 2004 to 2022 identified 1,175 drugs linked to AP, with metformin having the most reports, followed by quetiapine and others, mainly from diabetes medications.
- The study found that 595 drugs showed a potential risk for AP, with antineoplastic agents having the most positive signals, providing valuable insights for clinical practice regarding drug safety.
Article Synopsis
- * A total of 8,063 CDI cases linked to 73 antibacterial drugs were analyzed, with metronidazole showing the highest number of reports and positive adverse reaction signals.
- * The findings suggest that the CDI risk associated with metronidazole and vancomycin may be underestimated and warrant further investigation.
Article Synopsis
- - The study aims to identify drugs that cause severe cutaneous adverse reactions (SCARs) by analyzing data from the FDA Adverse Event Reporting System from 2004 to 2021, providing valuable information for clinical practice.
- - A total of 77,789 SCAR-related reports were analyzed, revealing that lamotrigine, acetaminophen, and allopurinol were among the most frequently reported drugs, with antibacterials being the most common drug class associated with SCARs.
- - The research identified 1,219 drugs linked to SCARs, with disproportionality analysis highlighting 776 drugs with positive pharmacovigilance signals, thus offering insights into the risk characteristics of SCARs for